

## QleanAir signs new \$503,000 agreement with a large east coast IDN for an investigational drug cleanroom

QleanAir Scandinavia, the provider of solutions for clean indoor air, has signed an agreement with a large university hospital system on the east coast to build a large, investigational drug cleanroom. The project is planned for Q1 of 2024.

QleanAir is dedicated to helping its customers protect people, products, and processes through cleanrooms that meet and exceed USP (United States Pharmacopeia) guidelines and maintain a compliant state of control. To that end, a large university hospital system on the east coast has signed an agreement with QleanAir.

To stay compliant with the new USP revisions while allowing for future modification of the cleanroom' s floorplan, the healthcare system signed a \$503,000 agreement with QleanAir to build an investigational drug cleanroom suite which planned to be built in 2024. This is one of several QleanAir cleanroom projects purchased by this customer.

"Our mission is to provide high-quality, purpose-built cleanroom solutions that comply with regulatory standards and offer exceptional performance," says Amanda Myers, Chief Commercial Officer of QleanAir Scandinavia Inc. We do not take our commitment to healthcare or the trusted partnerships of our customers for granted.

## For more information, please contact

Sebastian Lindström, CEO sebastian.lindstrom@qleanair.com +46 703 08 94 51

## About QleanAir

QleanAir is a niche premium provider of clean indoor environment solutions. The company's business model is based on lease contracts for modular solutions with a full-service offer. QleanAir solutions are developed using filter technology that traps, filters and recycles indoor air. The company has close to 12,000 installed units at more than 3,500 customers on the markets for EMEA, APAC and the Americas. For full year 2022, net sales amounted to 455 MSEK and adjusted operating margin was 10.9 percent. QleanAir's head office is in Solna in Sweden, and the share is traded on Nasdaq First North Premier Growth Market, ticker QAIR. FNCA Sweden is Certified Adviser +46 8 528 00 399. For more information go to qleanair.com.

## Attachments

<u>QleanAir signs new \$503,000 agreement with a large east coast IDN for an investigational drug</u> <u>cleanroom</u>